Smoking and tardive dyskinesia: Lack of involvement of the CYP1A2 gene

Journal of Psychiatry and Neuroscience

Volumn 28, Issue 3, 2003, Pages 185-189

  Chong, Siow Ann ^a   Tan, Ene Choo ^b   Tan, Chay Hoon ^c   Mythily, ^a  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

^b DEFENCE SCIENCE AND TECHNOLOGY AGENCY   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

China; Cytochrome P 450 CYP1A2; Dyskinesias; Genetic predisposition to disease; Movement disorders; Schizophrenia; Smoking

Indexed keywords

ADULT; AGED; ALLELISM; ARTICLE; CHINESE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INFORMATION PROCESSING; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; RISK ASSESSMENT; SCHIZOPHRENIA; SCORING SYSTEM; SMOKING; STATISTICAL SIGNIFICANCE; TARDIVE DYSKINESIA; DYSKINESIA; GENE EXPRESSION; GENETICS; HOSPITALIZATION; MIDDLE AGED; TOBACCO; TOBACCO DEPENDENCE;

CYTOCHROME P450 1A2;

CYTOCHROME P-450 CYP1A2; DYSKINESIA, DRUG-INDUCED; FEMALE; GENE EXPRESSION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PREVALENCE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SMOKING; TOBACCO; TOBACCO USE DISORDER;

EID: 0038507509     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Gopalaswamy AK, Morgan R. Smoking in chronic schizophrenia [letter]. Br J Psychiatry 1986:149:523.
2. De Leon J. Smoking and vulnerability for schizophrenia. Schizophr Bull 1996;22:405-9.
3. De Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM. Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry 1995;152:453-5.
4. Chong SA, Choo HL. Smoking among Chinese patients with schizophrenia. Australian N Z J Psychiatry 1996;30:350-3.
5. Masterson E, O'Shea B. Smoking and malignancy in schizophrenia. Br J Psychiatry 1984;145:429-32.
6. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986;143:993-7.
7. Goff DC, Henderson DC, Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 1992;149:1189-94.
8. Binder RL, Kazamatsuri H, Nishimura T, McNiel DE. Smoking and tardive dyskinesia. Biol Psychiatry 1987;22:1280-2.
9. Yassa R, Lal S, Korpassy A, Ally J. Nicotine exposure and tardive dyskinesia. Biol Psychiatry 1987;22:67-72.
10. Nilsson A, Waller L, Rosengren A, Adlerberth A, Wilhelmsen L. Cigarette smoking is associated with abnormal involuntary movements in the general male population - a study of men born in 1933. Biol Psychiatry 1997;41:717-23.
11. Bergen J, Kitchin R, Berry G. Predictors of the course of tardive dyskinesia in patients receiving neuroleptics. Biol Psychiatry 1992;32:580-94.
12. Rosengarten H, Schweitzer JW, Friedhoff AJ. Possible genetic factors underlying the pathophysiology of tardive dyskinesia. Pharmacol Biochem Behav 1994:49:663-7.
13. 2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry 1997;41:827-9.
14. 3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 1999;4:247-53.
15. Kapitany T, Meszaros K, Lenzinger E, Schindler SD, Barnas C, Fuchs K, et al. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 1998;32:101-6.
16. Arthur H, Dahl ML, Siwers B, Sjoqvist F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol 1995;15:211-6.
17. Ohmori O, Suzuki T, Kojima H, Shinkai T, Tera T, Mira T, et al. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotypes in Japanese schizophrenics. Schizophr Res 1998;32:107-13.
18. Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA, et al. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 2000;5:410-7.
19. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP 1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47:445-9.
20. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Washington: American Psychiatric Press; 1997.
21. Kane JM, Aguglia E, Altamura C, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW, et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 1998;8:55-66.
22. Guy W, editor. ECDEU assessment manual for psychopharmacology. Washington: US Department of Health, Education and Welfare; 1976. p. 534-7.
23. Simpson GM, Angus JWS. Drug-induced extrapyramidal disorder - a rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:20-7.
24. Schooler N, Kane JM. Research diagnosis for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486-7.
25. Menza MA, Grossman N, Van Horn M, Cody R, Forman N. Smoking and movement disorders in psychiatric patients. Biol Psychiatry 1991;30:109-15.
26. Ziedonis DM, Kosten TR, Glazer WM, Frances RJ. Nicotine dependence and schizophrenia. Hosp Community Psychiatry 1994;45:204-6.
27. Andersson K, Fuxe K, Agnati LF. Effects of single injections of nicotine on the ascending dopamine pathways in the rat. Evidence for increases of dopamine turnover in the mesostriatal and mesolimbic dopamine neurons. Acta Physiol Scand 1981;112:345-7.
28. Cadet JL, Lohr JB, Jeste DV. Free radicals and tardive dyskinesia. Trends Neurosci 1986;9:107-8.
29. Schulze TG, Schumacher J, Muller DJ, Krauss H, Alfter D, Maroldt A, et al. Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001;105:498-501.
30. Shimoda K, Someya T, Morita S, Hirokane G, Yokono A, Takahashi S, et al. Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position -2964 in the 5′-flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:261-5.
31. Kalow W, Tang BK. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 1991;49:44-8.
32. Chong SA, Sachdev P, Mahendran R, Chua HC. Neuroleptic and anticholinergic drug use in Chinese patients with schizophrenia resident in state psychiatric hospital in Singapore. Australia N Z J Psychiatry 2000;34:988-91.
33. Cozza KL, Armstrong SC. The cytochrome P450 system. Washington: American Psychiatric Publishing Inc.; 2001.
34. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 1999;125:803-8.